Integra LifeSciences (IART) to Release Earnings on Tuesday

Integra LifeSciences (NASDAQ:IART - Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Integra LifeSciences to post earnings of $0.86 per share and revenue of $445.15 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Integra LifeSciences Stock Down 4.1 %

Shares of NASDAQ IART traded down $0.90 during trading on Friday, hitting $21.13. 556,895 shares of the company traded hands, compared to its average volume of 539,465. The business's fifty day moving average is $23.71 and its 200 day moving average is $21.81. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.11. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -234.75, a P/E/G ratio of 0.76 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Analyst Ratings Changes

Several brokerages have recently weighed in on IART. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a report on Tuesday, November 5th. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences presently has an average rating of "Hold" and a consensus price target of $23.00.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.10% of the stock is currently owned by company insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.